Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The CDC's updated antimicrobial resistance report paints a sobering picture: nearly 10 million infections and over 50,000 deaths linked to drug-resistant pathogens in 2023 alone. That's a dramatic jump from the last report's estimates of 2.8 million infections and 35,000 deaths — though officials caution that expanded surveillance methods account for some of the increase. Healthcare-associated infections drove the bulk of the toll, costing nearly $12 billion.
The CDC has released its first antimicrobial resistance (AMR) threats report since 2019, and the numbers are striking. In 2023, nearly 9.7 million infections and 50,800 deaths were attributed to drug-resistant pathogens in the U.S. — compared to previous estimates of 2.8 million infections and 35,000 deaths. Officials urge caution in making direct comparisons, noting that expanded data sources and updated methodologies — such as including non-hospitalized C. difficile cases and noninvasive Streptococcus infections — account for a significant portion of the apparent increase.
Real increases are still present, particularly in healthcare settings, which accounted for more than 42,000 deaths and nearly $12 billion in costs. The report now tracks 19 pathogens across "urgent," "serious," and "concerning" tiers. Candida auris cases alone jumped tenfold since 2019, reaching 4,523 cases. On a brighter note, C. difficile was downgraded from "urgent" to "serious" after a 21% decline in rates from 2018 to 2020.
By the Numbers:
Why it matters: Drug-resistant infections don't just threaten patients with infections — they jeopardize the safety of routine procedures like chemotherapy, organ transplants, and joint replacements. Experts are calling on Congress to pass the PASTEUR Act to fund new antimicrobial drug development and stewardship programs before resistance outpaces medicine's ability to respond.
